<DOC>
	<DOCNO>NCT00436241</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Xeloda combination oxaliplatin first-line chemotherapy patient advance and/or metastatic gastric cancer prior chemotherapy advance metastatic disease . Eligible patient receive Xeloda 1000mg/m2 po twice daily , D1-D10 every 2 week ( 10 day treatment follow 4 day rest period ) plus oxaliplatin 85 mg/m2/day iv , D1 every 2 week . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) First-Line Chemotherapy Patients With Advanced Metastatic Gastric Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; gastric cancer unresectable locally advanced and/or metastatic disease ; &gt; =1 measurable lesion ; ambulatory , ECOG Performance Status &gt; =1 . previous chemotherapy ( except adjuvant neoadjuvant treatment &gt; =6 month prior enrollment ) ; clinically significant cardiac disease myocardial infarction within last 12 month ; CNS metastases ; history malignancy within last 5 year , except cure basal cell cancer skin , situ cancer cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>